European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Glaxosmithkline Intellectual Property Development Ltd., Stevenage

Watch
Glaxosmithkline Intellectual Property Development Ltd.

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Glaxosmithkline Intellectual Property Development Ltd.

Identification

Chp
Companies House 08283222
Lei
5493003KPICP2R6N1G28

Address

Gunnels Wood Road, Gsk Medicines Research Centre, Stevenage SG1 2NY, United Kingdom
980 Great West Road Brentford Middlesex, United Kingdom
Gsk Medicines Research Centre Gunnels Wood Road Stevenage, United Kingdom

Corporate purpose

64.20/9
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Total assets

For this company, Total assets numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
5Director
2Director
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Taxes
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

10 Sept 2026 also 22/09/2025, 11/10/2024, 05/10/2023, 23/09/2022, 24/09/2021, 08/10/2020, 23/09/2019, 03/12/2018
Confirmation statement made with no updates
Year 2026 in Epobase
7 European patent filings: Novel Processes for the Production of Oligonucleotides …
20 Aug 2026
Annual report for the year ending 31/12/2025
Year 2025 in Epobase
4 European patent filings: Interleukin 5 Binding Protein Dosage Regimen …
15 Aug 2025
Annual report for the year ending 31/12/2024
31 Jul 2025
Secretary's details changed for Edinburgh Pharmaceutical Industries Limited · Director's details changed for Edinburgh …
15 Jul 2025
Director: Anna M. H. Fent
9 Jul 2025
No longer Director: Jemma-L. Reynolds
Year 2024 in Epobase
22 European patent filings: Regimen for Treating a Neisseria Gonorrhoeae Infection with Gepotidacin …
27 Sept 2024
Director: C. Barcelo Igles
20 Sept 2024
Director's details changed for Mrs Demet Gurunlu Russ
17 Sept 2024
Director's details changed for Mr Graham Paul Rivers · Director's details changed for Mrs Jemma-Louise Reynolds …
22 Aug 2024
Annual report for the year ending 31/12/2023
31 Jul 2024
No longer Director: Gregory M. Reinaud
18 Jul 2024
Address
11 Jul 2024
Appointment of Mrs Demet Gurunlu Russ as a director
5 Jul 2024
No longer Director: Jill Dawn Anderson
15 Apr 2024
Director: Jemma-L. Reynolds
2 Feb 2024
Director: Gregory M. Reinaud
Year 2023 in Epobase
26 European patent filings: Methods of Treatment Using B-Cell Maturation Antigen Antagonists …
20 Sept 2023
No longer Director: Ziba Shamsi
16 Aug 2023
Annual report for the year ending 31/12/2022
16 Aug 2023
Companies House - Filing
2 Aug 2023
Director: Graham Paul Rivers
20 Jul 2023
No longer Director: James R. Wheatcroft
9 Jun 2023
Address
6 Jun 2023
Address
3 Mar 2023
Director: Jill Dawn Anderson
2 Mar 2023
No longer Director: Jerome Andries
Year 2023 in Euipods
8 registered designs
Year 2022 in Epobase
27 European patent filings: Stable Cell Lines for Retroviral Production …
3 Nov 2022
Director: Ziba Shamsi
2 Nov 2022
Termination of appointment of Kate Sophie Priestman as a director
15 Aug 2022
Annual report for the year ending 31/12/2021
Year 2021 in Epobase
28 European patent filings: Interleukin 5 Binding Protein Dosage Regimen …
29 Sept 2021
Annual report for the year ending 31/12/2020
Year 2020 in Epobase
45 European patent filings: Compounds …
6 Nov 2020
Annual report for the year ending 31/12/2019
Year 2019 in Epobase
45 European patent filings: Fluticasone Furoate in the Treatment of Copd …
24 Sept 2019
Annual report for the year ending 31/12/2018
3 Sept 2019
Director: James R. Wheatcroft
7 May 2019
No longer Director: Simon Paul Dingemans
Year 2018 in Epobase
71 European patent filings: Heterocyclic Amides AS Kinase Inhibitors …
5 Oct 2018
Annual report for the year ending 31/12/2017
30 Jan 2018
Director's details changed for Mr Jerome Charles Maurice Andries
Year 2017 in Epobase
57 European patent filings: Hdac Inhibitors …
17 Nov 2017
Director: Jerome Andries
16 Nov 2017
No longer Director: Luigi F. la Corte
28 Sept 2017
Annual report for the year ending 31/12/2016
7 Jan 2017
Appointment of Kate Sophie Priestman as a director
Year 2016 in Epobase
62 European patent filings: Pyridine Derivatives AS Rearranged During Transfection (RET) Kinase Inhibitors …
18 Nov 2016
Confirmation statement made with updates
2 Nov 2016
No longer Director (1)
28 Sept 2016 also 24/09/2015, 16/08/2014
Full accounts made up to 2015-12-31
8 Feb 2016
No longer Director (1)
Year 2015 in Epobase
26 European patent filings: Thiotriazole Compound and ITS USE in Parasitic Protozoal Infections …
1 Dec 2015
Capital: £100.00
15 May 2015
Director: Luigi F. la Corte
4 Dec 2014
Capital: £100.00
Year 2014 in Epobase
21 European patent filings: PI3K Inhibitor for Treatment of Respiratory Disease …
2 Jul 2014
Previous accounting period extended from 2013-11-30 to 2013-12-31
Year 2013 in Epobase
13 European patent filings: Vitamin Formulation …
17 Dec 2013
Capital: £100.00
17 May 2013
Director (1)
1 May 2013
Director: Adam Walker
6 Nov 2012
Reg­is­tra­tion: 06/11/2012 · Director (2) · Director: Edinburgh Pharmaceutical Industries Ltd., Glaxo Group Ltd. · Secretary: Edinburgh Pharmaceutical Industries Ltd
There are no publications matching your search.

Mentions

31 Jul 2023 in Ler
Direct parent
31 Jul 2023 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.